Our Resources | Association for Accessible Medicines

COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.

Feb 20, 2020 | Craig Burton

White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients

Jan 23, 2020 | Craig Burton

White Paper: Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution

Sep 20, 2019 | Craig Burton

White Paper: Access Denied: Why New Generics Are Not Reaching America's Seniors

Sep 18, 2019 | Erica Klinger

Report: 2019 Generic Drug & Biosimilars Access & Savings in the U.S.

White Paper: Biosimilars Council Failure to Launch Part 2

Sep 9, 2019 | Craig Burton

White Paper Part 2: Failure to Launch: Barriers to Biosimilar Market Adoption

Jun 25, 2019 | Christine Simmon

White Paper (Part 1) Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients

Quality Generic Drug Manufacturing

Apr 27, 2019 | Allen Goldberg

Commitment to Quality Excellence

Fix the USMCA trade agreement

Apr 24, 2019 | Erica Klinger

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

Apr 11, 2019 | Erica Klinger

AAM Code of Business Ethics

Jun 28, 2018 | Erica Klinger

2018 Generic Drug Access and Savings Report

Biosimilars Handbook - The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products

Apr 26, 2018 | Erica Klinger

Biosimilars Handbook

Apr 16, 2018 | Erica Klinger

2016 Savings and Access Report